The Gut Microbiome as a Target for IBD Treatment: Are We There Yet?

RSS de esta página

PubMed ID: 30661163

Imagen Publicación

Knox NC, Forbes JD, Van Domselaar G, Bernstein CN

Curr Treat Options Gastroenterol. Jan 2019. doi: 10.1007/s11938-019-00221-w

COMMENT: This review selects the most important and recent findings about the application of microbiome in Inflammatory bowel disease (IBD):

  • microbiome analysis as clinical diagnostic test for IBD
  • microbiome as biomarker for monitoring IBD
  • microbiome to design personalized therapies for IBD


This review aims to highlight current research on Inflammatory bowel disease (IBD) gut microbiome and summarize recent reports on therapies targeting the microbiome for the treatment of IBD


Fecal microbial transplantation (FMT) is currently emerging as one of the more promising microbiome-modulating IBD therapies. FMT studies in ulcerative colitis have shown improved remission rates compared to placebo single species to date has been convincingly identified as a biomarker in IBD or any of its component diseases. However, continued interest exists in developing the gut microbiome as a clinical diagnostic test for disease severity and for monitoring treatment response for IBD...


Researchers and clinicians have great hope that manipulating the gut microbiome will provide an answer to the mystery of IBD and reduce reliance on immunomodulating therapy. Given the heterogeneity of patients, phenotypes and genotypes, a more complex personalized medicine approach to microbiome manipulation will be an aspect to consider in the future.


Raquel Tobes